Cargando…
Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE
OBJECTIVE: Cognitive dysfunction (CD) is detectable in approximately 40% of patients with SLE. Despite this high prevalence, there are no approved pharmacological treatment options for this detrimental condition. Preliminary murine studies show potential for targeting microglial activation as a trea...
Autores principales: | Dobrowolski, Chrisanna, Barraclough, Michelle, Su, Jiandong, Tanic, Milica, Bingham, Kathleen, Ruttan, Lesley, Beaton, Dorcas, Wither, Joan, Tartaglia, Maria Carmela, Sano, Mary, Kakvan, Mahta, Bonilla, Dennisse, Green, Robin, Touma, Zahi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335417/ https://www.ncbi.nlm.nih.gov/pubmed/37429671 http://dx.doi.org/10.1136/lupus-2023-000923 |
Ejemplares similares
-
Insight into intraindividual variability across neuropsychological tests and its association with cognitive dysfunction in patients with lupus
por: He, Jennifer Wei, et al.
Publicado: (2021) -
Validation of the automated neuropsychological assessment metrics for assessing cognitive impairment in systemic lupus erythematosus
por: Yuen, Kimberley, et al.
Publicado: (2021) -
ACEIs and ARBs and Their Correlation with COVID-19: A Review
por: Yehualashet, Awgichew Shewasinad, et al.
Publicado: (2020) -
The role of ACEIs/ARBs in COVID-19: Friend or foe?
por: Zhou, Zhe, et al.
Publicado: (2020) -
Withdrawal of ACEIs or ARBs in hospitalised patients with COVID-19
Publicado: (2021)